NCT02625935View on ClinicalTrials.gov

Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

CompletedOBSERVATIONAL
Enrollment

206

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

October 10, 2017

Conditions
Breast Cancer
Trial Locations (4)

11733

North Shore Hematology Oncology Assoaciates, East Setauket

20817

Center for Cancer and Blood Disorders, Bethesda

33913

Florida Cancer Center, Fort Myers

04074

New England Cancer Specialists, Scarborough

Sponsors
All Listed Sponsors
lead

NanoString Technologies, Inc.

INDUSTRY

NCT02625935 - Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients | Biotech Hunter | Biotech Hunter